Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Detalles Bibliográficos
Autores principales: Miao, Yi, Sha, Yeqin, Xia, Yi, Qin, Shuchao, Jiang, Rui, Dai, Luomengjia, Shen, Hui, Qiu, Tonglu, Wu, Wei, Qiu, Jingyan, Yang, Yilian, Ding, Chongyang, Wu, Yujie, Fan, Lei, Xu, Wei, Li, Jianyong, Zhu, Huayuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412547/
https://www.ncbi.nlm.nih.gov/pubmed/37558684
http://dx.doi.org/10.1038/s41408-023-00890-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412547/
https://www.ncbi.nlm.nih.gov/pubmed/37558684
http://dx.doi.org/10.1038/s41408-023-00890-y

Ejemplares similares